Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 16:9:2658.
doi: 10.3389/fimmu.2018.02658. eCollection 2018.

Novel Treatments in Lupus

Milena Vukelic  1 , Yi Li  1 , Vasileios C Kyttaris  1
Affiliations
Review

Novel Treatments in Lupus

Milena Vukelic et al. Front Immunol. .

Abstract

The standard treatment options for systemic lupus erythematosus (SLE) are focused on non-specific immunosuppression. Over the past few years, scientific studies and ongoing clinical trials have shifted the paradigm with rapid advances in developing biologics and small molecules. A number of monoclonal antibodies and small molecule inhibitors have been developed to target specific pathways involved in SLE. Many of these novel therapeutic agents are already being tested in clinical trials and they may 1 day reshape the landscape of SLE treatment. Herein we review potential future therapeutic options for SLE.

Keywords: biologics; clinical trails; lupus; small molecules; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Therapeutic targets and novel treatments in SLE. Target molecules (black) and corresponding therapeutic agents (red) in clinical trials are illustrated. pDC, plasmacytoid dendritic cell; MHC, major histocompatibility complex; CD, cluster of differentiation; APRIL, a proliferating-induced ligand; BLys, B-lymphocyte stimulator; IL, interleukin; TCR, T cell receptor; IFNAR1, Interferon alpha receptor 1; BTK, Bruton's tyrosine kinase; mTOR, mammalian target of rapamycin; Jak, Janus kinases; STAT, signal transducer and activator of transcription proteins; Ub, ubiquitin; E3, Ubiquitin protein ligases.
See this image and copyright information in PMC

References

    1. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. . A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. (2011) 63:3918–30. 10.1002/art.30613 - DOI - PMC - PubMed
    1. Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et al. . Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. (2017) 69:1016–27. 10.1002/art.40049 - DOI - PMC - PubMed
    1. Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, et al. . Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus. Arthritis Rheumatol. (2018) 70:1256–64. 10.1002/art.40511 - DOI - PMC - PubMed
    1. Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, et al. . Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. (2016) 75:323–31. 10.1136/annrheumdis-2015-207653 - DOI - PubMed
    1. Isenberg D. Further thoughts about the ILLUMINATE studies of tabalumab in SLE. Ann Rheum Dis. (2016) 75:e11. 10.1136/annrheumdis-2015-208709 - DOI - PubMed

MeSH terms